International Journal of Rheumatology最新文献_第10页

Vaccination of Adult Patients with Systemic Lupus Erythematosus in Portugal. 葡萄牙成年系统性红斑狼疮患者的疫苗接种。

IF 2.3

International Journal of Rheumatology Pub Date : 2016-01-01 Epub Date: 2016-03-16 DOI: 10.1155/2016/2845617

Maria Francisca Moraes-Fontes, Ana Margarida Antunes, Heidi Gruner, Nuno Riso

引用次数: 5

Association between Air Pollution and the Development of Rheumatic Disease: A Systematic Review. 空气污染与风湿病发病之间的关系：系统回顾

IF 2.3

International Journal of Rheumatology Pub Date : 2016-01-01 Epub Date: 2016-10-25 DOI: 10.1155/2016/5356307

Gavin Sun, Glen Hazlewood, Sasha Bernatsky, Gilaad G Kaplan, Bertus Eksteen, Cheryl Barnabe

{"title":"Association between Air Pollution and the Development of Rheumatic Disease: A Systematic Review.","authors":"Gavin Sun, Glen Hazlewood, Sasha Bernatsky, Gilaad G Kaplan, Bertus Eksteen, Cheryl Barnabe","doi":"10.1155/2016/5356307","DOIUrl":"10.1155/2016/5356307","url":null,"abstract":"Objective. Environmental risk factors, such as air pollution, have been studied in relation to the risk of development of rheumatic diseases. We performed a systematic literature review to summarize the existing knowledge. Methods. MEDLINE (1946 to September 2016) and EMBASE (1980 to 2016, week 37) databases were searched using MeSH terms and keywords to identify cohort, case-control, and case cross-over studies reporting risk estimates for the development of select rheumatic diseases in relation to exposure of measured air pollutants (n = 8). We extracted information on the population sample and study period, method of case and exposure determination, and the estimate of association. Results. There was no consistent evidence of an increased risk for the development of rheumatoid arthritis (RA) with exposure to NO2, SO2, PM2.5, or PM10. Case-control studies in systemic autoimmune rheumatic diseases (SARDs) indicated higher odds of diagnosis with increasing PM2.5 exposure, as well as an increased relative risk for juvenile idiopathic arthritis (JIA) in American children <5.5 years of age. There was no association with SARDs and NO2 exposure. Conclusion. There is evidence for a possible association between air pollutant exposures and the development of SARDs and JIA, but relationships with other rheumatic diseases are less clear.","PeriodicalId":51715,"journal":{"name":"International Journal of Rheumatology","volume":"2016 1","pages":"5356307"},"PeriodicalIF":2.3,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64424735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Behcet's Disease: Is There Geographical Variation? A Review Far from the Silk Road 白塞氏病:是否存在地理差异?远离丝绸之路

IF 2.3

International Journal of Rheumatology Pub Date : 2015-12-20 DOI: 10.1155/2015/945262

Nieves Leonardo, Julian McNeil

引用次数: 71

Clinical Assessment and Management of Spondyloarthritides in the Middle East: A Multinational Investigation 中东地区脊椎关节炎的临床评估和治疗:一项多国调查

IF 2.3

International Journal of Rheumatology Pub Date : 2015-12-17 DOI: 10.1155/2015/178750

M. Hammoudeh, H. Al Rayes, A. Alawadhi, K. Gado, Khalid Shirazy, A. Deodhar

{"title":"Clinical Assessment and Management of Spondyloarthritides in the Middle East: A Multinational Investigation","authors":"M. Hammoudeh, H. Al Rayes, A. Alawadhi, K. Gado, Khalid Shirazy, A. Deodhar","doi":"10.1155/2015/178750","DOIUrl":"https://doi.org/10.1155/2015/178750","url":null,"abstract":"Data on spondyloarthritis (SpA) from the Middle East are sparse and the management of these diseases in this area of the world faces a number of challenges, including the relevant resources to enable early diagnosis and referral and sufficient funds to aid the most appropriate treatment strategy. The objective was to report on the characteristics, disease burden, and treatment of SpA in the Middle East region and to highlight where management strategies could be improved, with the overall aim of achieving better patient outcomes. This multicenter, observational, cross-sectional study collected demographic, clinical, laboratory, and treatment data on 169 consecutive SpA patients at four centers (Egypt, Kuwait, Qatar, and Saudi Arabia). The data collected presents the average time from symptom onset to diagnosis along with the presence of comorbidities in the region and comparisons between treatment with NSAIDs and biologics. In the absence of regional registries of SpA patients, the data presented here provide a rare snapshot of the characteristics, disease burden, and treatment of these patients, highlighting the management challenges in the region.","PeriodicalId":51715,"journal":{"name":"International Journal of Rheumatology","volume":"2015 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2015-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/178750","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64826141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Serum Markers in Rheumatoid Arthritis: A Longitudinal Study of Patients Undergoing Infliximab Treatment 类风湿关节炎的血清标志物:一项接受英夫利昔单抗治疗的患者的纵向研究

IF 2.3

International Journal of Rheumatology Pub Date : 2015-12-16 DOI: 10.1155/2015/276815

Oddgeir Selaas, H. H. Nordal, A. Halse, J. Brun, R. Jonsson, K. Brokstad

{"title":"Serum Markers in Rheumatoid Arthritis: A Longitudinal Study of Patients Undergoing Infliximab Treatment","authors":"Oddgeir Selaas, H. H. Nordal, A. Halse, J. Brun, R. Jonsson, K. Brokstad","doi":"10.1155/2015/276815","DOIUrl":"https://doi.org/10.1155/2015/276815","url":null,"abstract":"Objective. The aim of this study was to investigate the clinical effect and serum markers in a cohort of rheumatoid arthritis patients with moderate to high disease activity, participating in an open clinical phase IV study conducted in Norway between 2001 and 2003 receiving infliximab treatment. Method. A total of 39 patients were studied, with a mean age of 54 years and 12-year disease duration. The analyses were performed using serum from patients at four assessment time points: baseline and 3, 6, and 12 months after starting treatment with infliximab. A wide variety of clinical data was collected and disease activity of 28 joints and Simple Disease Activity Index were calculated. The joint erosion was determined by X-ray imaging and the Sharp/van der Heijde score was determined. Serum analysis included multiplex immunoassays for 12 cytokines, 5 matrix metalloproteases, and 2 VEGFs. Results. The majority of the RA patients in this study had initially moderate to high disease activity and the infliximab treatment reduced the disease activity significantly and also reduced any further joint destruction and improved disease status. Most of the serum levels of cytokines and metalloproteases remained unchanged during the course of the study, and we were unable to detect changes in TNF-α in serum. Serum levels of IL-6 and VEGF-A decreased significantly after initiation of infliximab treatment. Conclusion. The serum levels of IL-6 and VEGF-A may be promising disease markers as they vary with disease progression. The clinical significance of these findings is yet to be determined and has to be confirmed in future clinical trials before being applied in the clinics.","PeriodicalId":51715,"journal":{"name":"International Journal of Rheumatology","volume":"2015 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2015-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/276815","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64878250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Gastric Antral Vascular Ectasia in Systemic Sclerosis: Current Concepts 系统性硬化症的胃窦血管扩张:当前概念

IF 2.3

International Journal of Rheumatology Pub Date : 2015-11-08 DOI: 10.1155/2015/762546

Raphael H. Parrado, H. N. Lemus, P. Coral-Alvarado, G. Quintana López

{"title":"Gastric Antral Vascular Ectasia in Systemic Sclerosis: Current Concepts","authors":"Raphael H. Parrado, H. N. Lemus, P. Coral-Alvarado, G. Quintana López","doi":"10.1155/2015/762546","DOIUrl":"https://doi.org/10.1155/2015/762546","url":null,"abstract":"Introduction. Gastric antral vascular ectasia (GAVE) is a rare entity with unique endoscopic appearance described as “watermelon stomach.” It has been associated with systemic sclerosis but the pathophysiological changes leading to GAVE have not been explained and still remain uncertain. Methods. Databases Medline, Scopus, Embase, PubMed, and Cochrane were searched for relevant papers. The main search words were “Gastric antral vascular ectasia,” “Watermelon Stomach,” “GAVE,” “Scleroderma,” and “Systemic Sclerosis.” Fifty-four papers were considered for this review. Results. GAVE is a rare entity in the spectrum of manifestations of systemic sclerosis with unknown pathogenesis. Most patients with systemic sclerosis and GAVE present with asymptomatic anemia, iron deficiency anemia, or heavy acute gastrointestinal bleeding. Symptomatic therapy and endoscopic ablation are the first-line of treatment. Surgical approach may be recommended for patients who do not respond to medical or endoscopic therapies. Conclusion. GAVE can be properly diagnosed and treated. Early diagnosis is key in the management of GAVE because it makes symptomatic therapies and endoscopic approaches feasible. A high index of suspicion is critical. Future studies and a critical review of the current findings about GAVE are needed to understand the role of this condition in systemic sclerosis.","PeriodicalId":51715,"journal":{"name":"International Journal of Rheumatology","volume":"91 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2015-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/762546","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65141755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Improving the Measurement of Disease Activity for Patients with Rheumatoid Arthritis: Validation of an Electronic Version of the Routine Assessment of Patient Index Data 3 改善类风湿关节炎患者疾病活动度的测量:患者指标数据常规评估电子版本的验证

IF 2.3

International Journal of Rheumatology Pub Date : 2015-11-08 DOI: 10.1155/2015/834070

Ruthie M Chua, John N. Mecchella, A. Zbehlik

引用次数: 5

Intravenous iron administration and hypophosphatemia in clinical practice. 临床实践中的静脉给铁与低磷血症。

IF 2.3

International Journal of Rheumatology Pub Date : 2015-01-01 Epub Date: 2015-04-27 DOI: 10.1155/2015/468675

S Hardy, X Vandemergel

{"title":"Intravenous iron administration and hypophosphatemia in clinical practice.","authors":"S Hardy, X Vandemergel","doi":"10.1155/2015/468675","DOIUrl":"https://doi.org/10.1155/2015/468675","url":null,"abstract":"Introduction. Parenteral iron formulations are frequently used to correct iron deficiency anemia (IDA) and iron deficiency (ID). Intravenous formulation efficacy on ferritin and hemoglobin level improvement is greater than that of oral formulations while they are associated with lower gastrointestinal side effects. Ferric carboxymaltose- (FCM-) related hypophosphatemia is frequent and appears without clinical significance. The aim of this study was to assess the prevalence, duration, and potential consequences of hypophosphatemia after iron injection. Patients and Methods. The medical records of all patients who underwent parenteral iron injection between 2012 and 2014 were retrospectively reviewed. Pre- and postinjection hemoglobin, ferritin, plasma phosphate, creatinine, and vitamin D levels were assessed. Patients who developed moderate (range: 0.32-0.80 mmol/L) or severe (<0.32 mmol/L) hypophosphatemia were questioned for symptoms. Results. During the study period, 234 patients received iron preparations but 104 were excluded because of missing data. Among the 130 patients included, 52 received iron sucrose (FS) and 78 FCM formulations. Among FS-treated patients, 22% developed hypophosphatemia versus 51% of FCM-treated patients, including 13% who developed profound hypophosphatemia. Hypophosphatemia severity correlated with the dose of FCM (p = 0.04) but not with the initial ferritin, hemoglobin, or vitamin D level. Mean hypophosphatemia duration was 6 months. No immediate clinical consequence was found except for persistent fatigue despite anemia correction in some patients. Conclusions. Hypophosphatemia is frequent after parenteral FCM injection and may have clinical consequences, including persistent fatigue. Further studies of chronic hypophosphatemia long-term consequences, especially bone assessments, are needed. ","PeriodicalId":51715,"journal":{"name":"International Journal of Rheumatology","volume":"2015 ","pages":"468675"},"PeriodicalIF":2.3,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/468675","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33206073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 60

Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East. Tocilizumab治疗类风湿关节炎的安全性、耐受性和有效性:中东患者的一项开放标签4期研究

IF 2.3

International Journal of Rheumatology Pub Date : 2015-01-01 Epub Date: 2015-05-19 DOI: 10.1155/2015/975028

Mohammed Hammoudeh, Adel Al Awadhi, Eman Haji Hasan, Maassoumeh Akhlaghi, Arman Ahmadzadeh, Bahar Sadeghi Abdollahi

{"title":"Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East.","authors":"Mohammed Hammoudeh, Adel Al Awadhi, Eman Haji Hasan, Maassoumeh Akhlaghi, Arman Ahmadzadeh, Bahar Sadeghi Abdollahi","doi":"10.1155/2015/975028","DOIUrl":"https://doi.org/10.1155/2015/975028","url":null,"abstract":"This open-label study investigated the safety and efficacy of tocilizumab in Middle Eastern patients with rheumatoid arthritis (RA). Patients whose Disease Activity Score based on 28 joints (DAS28) was >3.2 received tocilizumab 8 mg/kg intravenously every 4 weeks for 24 weeks. Patients receiving aTNF ± nonbiologic disease-modifying antirheumatic drug(s) (DMARD(s)) switched to tocilizumab; patients receiving nonbiologic DMARD monotherapy added tocilizumab. Primary end points were adverse events (AEs), serious AEs (SAEs), and laboratory parameters; secondary end points were DAS28, Health Assessment Questionnaire-Disability Index, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). Eighty-eight of 95 patients completed 24 weeks. Overall, 125 AEs were reported in 43 (45%) patients; the most common were increased hepatic enzymes (16%) and cholesterol (11%). Eight patients experienced SAEs. Significant changes from baseline to week 24 occurred for hemoglobin, neutrophils, platelets, total cholesterol, and liver enzymes (P < 0.05). DAS28, CRP, and ESR decreased significantly from baseline at each visit (P < 0.0001). At week 24, the proportions of patients reporting DAS28 clinically meaningful improvement (decrease ≥1.2), low disease activity (DAS28 ≥2.6 to ≤3.2), and remission (DAS28 <2.6) were 92%, 23%, and 64%, respectively. Safety and efficacy of tocilizumab were consistent with values reported in Western patients. ","PeriodicalId":51715,"journal":{"name":"International Journal of Rheumatology","volume":"2015 ","pages":"975028"},"PeriodicalIF":2.3,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/975028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33402679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Rheumatic Heart Disease in Kerala: A Vanishing Entity? An Echo Doppler Study in 5-15-Years-Old School Children. 喀拉拉邦的风湿性心脏病:一个正在消失的实体?5-15岁学龄儿童的回声多普勒研究

IF 2.3

International Journal of Rheumatology Pub Date : 2015-01-01 Epub Date: 2015-09-14 DOI: 10.1155/2015/930790

Bigesh Nair, Sunitha Viswanathan, A George Koshy, Prabha Nini Gupta, Namita Nair, Ashok Thakkar

{"title":"Rheumatic Heart Disease in Kerala: A Vanishing Entity? An Echo Doppler Study in 5-15-Years-Old School Children.","authors":"Bigesh Nair, Sunitha Viswanathan, A George Koshy, Prabha Nini Gupta, Namita Nair, Ashok Thakkar","doi":"10.1155/2015/930790","DOIUrl":"https://doi.org/10.1155/2015/930790","url":null,"abstract":"Background. Early detection of subclinical rheumatic heart disease by use of echocardiography warrants timely implementation of secondary antibiotic prophylaxis and thereby prevents or retards its related complications. Objectives. The objective of this epidemiological study was to determine prevalence of RHD by echocardiography using World Heart Federation criteria in randomly selected school children of Trivandrum. Methods. This was a population-based cross-sectional screening study carried out in Trivandrum. A total of 2060 school children, 5-15 years, were randomly selected from five government and two private (aided) schools. All enrolled children were screened for RHD according to standard clinical and WHF criteria of echocardiography. Results. Echocardiographic examinations confirmed RHD in 5 children out of 146 clinically suspected cases. Thus, clinical prevalence was found to be 2.4 per 1000. According to WHF criteria of echocardiography, 12 children (12/2060) were diagnosed with RHD corresponding to echocardiographic prevalence of 5.83 cases per 1000. As per criteria, 6 children were diagnosed with definite RHD and 6 with borderline RHD. Conclusions. The results of the current study demonstrate that echocardiography is more sensitive and feasible in detecting clinically silent RHD. Our study, the largest school survey of south India till date, points towards declining prevalence of RHD (5.83/1000 cases) using WHF criteria in Kerala. ","PeriodicalId":51715,"journal":{"name":"International Journal of Rheumatology","volume":"2015 ","pages":"930790"},"PeriodicalIF":2.3,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/930790","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34244884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16